We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+15.9%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.81B
AUM Growth
+$276M
Cap. Flow
-$211M
Cap. Flow %
-4.39%
Top 10 Hldgs %
49.94%
Holding
159
New
17
Increased
40
Reduced
75
Closed
11

Top Buys

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$87M
2
RVMD icon
Revolution Medicines
RVMD
+$38.9M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$26.8M
4
AKRO
Akero Therapeutics
AKRO
+$19.6M
5
IMCR icon
Immunocore
IMCR
+$12.1M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$93.6M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$78.5M
3
BPMC
Blueprint Medicines
BPMC
+$36.5M
4
MRNA icon
Moderna
MRNA
+$34.3M
5
SYK icon
Stryker
SYK
+$32.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.85%
2 Miscellaneous 0.08%
3 Technology 0.03%
4 Consumer Discretionary 0.02%
5 Communication Services 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDXX icon
26
Idexx Laboratories
IDXX
$42.2B
$48.9M 1.02%
76,587
+39
+0.1% +$23.7K
RMD icon
27
ResMed
RMD
$32.9B
$45.1M 0.94%
164,834
-968
-0.6% -$264K
EWTX icon
28
Edgewise Therapeutics
EWTX
$4.68B
$45M 0.94%
2,775,997
– –
RLAY icon
29
Relay Therapeutics
RLAY
$4.17B
$43.6M 0.91%
8,345,610
+114,740
+1% +$438K
BHVN icon
30
Biohaven
BHVN
$2.37B
$42.1M 0.87%
2,802,853
– –
ABBV icon
31
AbbVie
ABBV
$453B
$39.6M 0.82%
170,870
+11,209
+7% +$2.28M
PEN icon
32
Penumbra
PEN
$12.7B
$37.2M 0.77%
146,895
-27,155
-16% -$6.85M
CI icon
33
Cigna
CI
$74.7B
$35.3M 0.73%
122,486
+11,774
+11% +$3.48M
GEHC icon
34
GE HealthCare
GEHC
$31.1B
$34.8M 0.72%
463,063
-52,405
-10% -$3.91M
ELV icon
35
Elevance Health
ELV
$88.4B
$33.9M 0.7%
104,971
+22,918
+28% +$7.13M
DHR icon
36
Danaher
DHR
$146B
$32.5M 0.68%
163,876
+27,065
+20% +$5.39M
LLY icon
37
Eli Lilly
LLY
$1.02T
$30.9M 0.64%
40,514
-406
-1% -$302K
WVE icon
38
Wave Life Sciences
WVE
$958M
$30M 0.62%
4,094,458
– –
MCK icon
39
McKesson
MCK
$106B
$29.3M 0.61%
37,957
-2,509
-6% -$1.77M
STE icon
40
Steris
STE
$21.9B
$29.2M 0.61%
118,112
+8,225
+7% +$1.97M
VEEV icon
41
Veeva Systems
VEEV
$44.5B
$29M 0.6%
97,506
-15,827
-14% -$4.45M
HCA icon
42
HCA Healthcare
HCA
$87.7B
$28M 0.58%
65,607
-33,515
-34% -$13M
ZBH icon
43
Zimmer Biomet
ZBH
$18.7B
$24.2M 0.5%
245,202
-22,514
-8% -$2.23M
COO icon
44
Cooper Companies
COO
$13.6B
$20M 0.42%
292,265
-63,809
-18% -$4.52M
HUM icon
45
Humana
HUM
$48.2B
$19.9M 0.41%
76,310
+27,186
+55% +$7.15M
GMED icon
46
Globus Medical
GMED
$10.5B
$18.7M 0.39%
326,867
-5,469
-2% -$315K
ALGN icon
47
Align Technology
ALGN
$11.3B
$18.1M 0.38%
144,676
-6,111
-4% -$957K
MOH icon
48
Molina Healthcare
MOH
$10.5B
$17.4M 0.36%
90,985
+16,963
+23% +$3.12M
HOLX
49
DELISTED
Hologic
HOLX
$16.7M 0.35%
247,886
– –
MGNX icon
50
MacroGenics
MGNX
$280M
$16.7M 0.35%
9,919,992
– –
1
2
3 4 5

Similar funds

SP
Stockbridge Partners Boston, Massachusetts $4.75B AUM 18.52% 1-Year Est. Return
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return
SAMU
SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return
LPPI
Local Pensions Partnership Investment London, United Kingdom $4.77B AUM 20.5% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
NHC
Nicholas Hoffman & Company Atlanta, Georgia $4.74B AUM 18.12% 1-Year Est. Return
PTC
Provident Trust Company Waukesha, Wisconsin $4.77B AUM 29.31% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Bellevue Group's Q3 2025 Portfolio in Review

As of Q3 2025, Bellevue Group held 159 positions worth $4.81B, up 6.1% from $4.54B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Bellevue Group withdrew a net $211M in Q3 2025, closing 11 positions and reducing 75 holdings. Its most notable exit was Blueprint Medicines, an estimated $36.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Bellevue Group opened a new position in Avidity Biosciences worth $93.8M.

  • Bellevue Group's largest Q3 2025 buy was Avidity Biosciences: 2,152,862 shares worth $93.8M.
  • Bellevue Group added most to Revolution Medicines in Q3 2025, an estimated $38.9M increase.
  • Bellevue Group's biggest Q3 2025 reduction was Alnylam Pharmaceuticals, cutting an estimated $93.6M.
  • Bellevue Group fully exited Blueprint Medicines in Q3 2025, selling an estimated $36.5M.
  • Bellevue Group's ten largest holdings make up 50% of its $4.81B portfolio in Q3 2025.
  • Bellevue Group opened 17 new positions and closed 11 in Q3 2025.
  • Bellevue Group's portfolio value rose 6.1% quarter-over-quarter to $4.81B.

Based on Bellevue Group's 13F filing for Q3 2025, filed 14 Nov 2025.